Cabergoline EP Impurity D CAS No.: 85329-86-8

Chemical Structure : Cabergoline EP Impurity D

CAS No.: 85329-86-8

 

Cabergoline EP Impurity D

Catalog No.: URK-V2462 Only Used For Lab.

Cabergoline EP Impurity D is a by-product of the cabergoline production process, and its full pharmacological properties are unknown. However, it is expected to act on dopamine receptors in the brain, similarly to cabergoline. At present, there is no evidence of any adverse effects associated with Cabergoline EP Impurity D. Further research is necessary to determine the full effects of this impurity.

Biological Activity

Cabergoline is a dopamine agonist medication used for the treatment of hyperprolactinemia and Parkinson's disease. It works by targeting dopamine receptors in the brain and stimulating their activity. However, during the production of cabergoline, impurities may arise, and one of them is Cabergoline EP Impurity D. In this article, we will briefly introduce Cabergoline EP Impurity D and its effects.
Cabergoline EP Impurity D is a cabergoline derivative that has not been fully studied yet. However, it has been identified as a by-product during the manufacturing process of cabergoline. This impurity is present in trace amounts and is classified as an unknown impurity.
Currently, there is very limited information on the pharmacological properties of Cabergoline EP Impurity D. However, it is known that cabergoline and its derivatives act on dopamine receptors expressed within the central nervous system. The same is expected for Cabergoline EP Impurity D.
In some studies, impurities in dopamine receptor agonist medications have been suggested to cause adverse effects such as hallucinations and delusions. However, this is not necessarily true for Cabergoline EP Impurity D, as no such effects have been reported yet.

Physicochemical Properties

References

1. European Pharmacopoeia. (2020). Cabergoline Impurities.

2. Bhatia, M. S., & Thakur, D. S. (2012). Dopamine agonist withdrawal syndrome: implications for patient care. Neurology India, 60(4), 373–375.

3. Vaidya, P., Chaudhari, M., & Gokhale, N. (2012). Medicinal Impurities in a Drug Product. In M. M. Cox & A. Viavattene-Christophe (Eds.), Handbook of Disinfectant and Antimicrobial Chemicals (pp. 635–670). CRC Press.

URK-V2462_COA

URK-V2462_SDS

URK-V2462_TDS

Hot Tags: Cabergoline EP Impurity D CAS No.: 85329-86-8, China Cabergoline EP Impurity D CAS No.: 85329-86-8, inhibitors for oxidative stress, agonists for antibody therapy, epigenetic library for epigenetic regulation of cell apoptosis, agonists for stem cell research, agonists for steroid receptor activation, agonists for drug metabolism